• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/7/25 4:07:15 PM ET
    $INGN
    Industrial Specialties
    Health Care
    Get the next $INGN alert in real time by email
    8-K
    false0001294133Inogen Inc00012941332025-05-072025-05-07

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 07, 2025

     

     

    INOGEN, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-36309

    33-0989359

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    859 Ward Drive

     

    Goleta, California

     

    93111

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (805) 562-0500

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value

     

    INGN

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02. Results of Operations and Financial Condition.

    On May 7, 2025, Inogen, Inc. (the "Company") issued a press release reporting its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

    The information set forth under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

     

     Description

    99.1

    Press Release dated May 7, 2025.

    104

    The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    INOGEN, INC.

     

     

     

     

    Date:

    May 7, 2025

    By:

    /s/ Michael Bourque

     

     

     

    Michael Bourque
    Executive Vice President
    Chief Financial Officer
    Treasurer
    (Principal Accounting and Financial Officer)

     


    Get the next $INGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INGN

    DatePrice TargetRatingAnalyst
    6/16/2025$14.00Buy
    B. Riley Securities
    5/22/2025$12.00Hold → Buy
    Needham
    2/15/2024Mkt Perform → Outperform
    William Blair
    8/8/2023$15.00 → $8.00Overweight → Neutral
    JP Morgan
    7/14/2023Buy → Hold
    Needham
    1/17/2023Outperform → Mkt Perform
    William Blair
    12/9/2021$47.00Hold → Buy
    Needham
    11/8/2021$70.00 → $40.00Hold
    Stifel
    More analyst ratings